Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06800105 · ClinicalTrials.gov registry record
Dysregulation of Whole-body Metabolism in Ovarian Cancer: A Longitudinal Study
A clinical trial of Ovary Cancer, sponsored by University of Tennessee Graduate School of Medicine.
- Recruiting
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT06800105: Recruiting study of Ovary Cancer, sponsored by University of Tennessee Graduate School of Medicine.
NCT06800105 is a study of Ovary Cancer that is actively recruiting participants, run by University of Tennessee Graduate School of Medicine. The registered enrollment target is 10 participants, below the 130-participant average among 10 other Ovary Cancer trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06800105, a study of Ovary Cancer, is actively recruiting participants, sponsored by University of Tennessee Graduate School of Medicine.
- RECRUITING
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Minimal information is available regarding changes in whole-body metabolism in ovarian cancer patients, and no study has assessed whole-body lipid metabolism in this patient population. In this pilot study we will assess fasting and postprandial lipid metabolism of ovarian cancer patients before, during, and after treatment via indirect calorimetry.
Primary Outcome
Feasibility assessed by ≤20% attrition (yes/no), defined as the percentage of enrolled participants, that are able to complete all three study visits.
Conditions Studied
Interventions
- OTHER High fat smoothie
Study Locations (1)
Tennessee
- University of Tennessee Graduate School of Medicine - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-03-22 |
| Est. Completion | 2028-03-31 |
What NCT06800105 shows while recruiting
NCT06800105 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 130-participant average among 10 other Ovary Cancer trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Ovary Cancer appearing as the primary indexed condition, and to 1 intervention - of which High fat smoothie is the first listed.
NCT06800105 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT06800105 about?
NCT06800105 is a clinical study titled "Dysregulation of Whole-body Metabolism in Ovarian Cancer: A Longitudinal Study". Minimal information is available regarding changes in whole-body metabolism in ovarian cancer patients, and no study has assessed whole-body lipid metabolism in this patient population. In this pilot study we will assess fasting and postprandial lipid metabolism of ovarian cancer patients before, du...
What is the current status of trial NCT06800105?
This trial is currently recruiting. The enrollment target is 10 participants. The study started on 2023-03-22. Estimated completion is 2028-03-31.
What conditions does trial NCT06800105 study?
This clinical trial studies the following conditions: Ovary Cancer.
What interventions are being tested in trial NCT06800105?
The interventions under investigation include: High fat smoothie (OTHER).
Who is sponsoring clinical trial NCT06800105?
This trial is sponsored by University of Tennessee Graduate School of Medicine, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06800105 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovary Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06800105's enrollment target sits among peer trials
10 10th of 10 higher than 1 of 10 other Ovary Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovary Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
RECRUITING · NA
-
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
RECRUITING · Phase 2
-
Multimedia Aid for Genetic Testing in Gynecologic Oncology
RECRUITING · NA
-
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
RECRUITING · NA
-
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
RECRUITING · Phase 2
-
Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI